CICC has recently helped Yiling Pharmaceutical to complete the A-share Non-Public Offering. It was completed on March 20, 2017, and the total offering is 74,720,183 shares of RMB 1,306,108,798.84. CICC acted as the sole Sponsor and Lead Underwriter for Yiling Pharmaceutical in the transaction.

Established by Dr. WU Yiling, an academician of Chinese Academy of Engineering, Yiling Pharmaceutical is engaged in R&D, manufacturing and distribution of Chinese patent medicine and ranks among Top 50 pharmaceutical innovative manufacturers in China. The Transaction is the first private placement for a traditional Chinese medicine player by CICC. CICC was highly recognized by Yiling Pharmaceutical’s management for its strong professionalism, extensive resources and full-around services. The deal represents the first cooperation between CICC and Yiling Pharmaceutical, paving the way for the future business opportunities and the long-term strategic partnership between the two parties.